Patent ID: 8772326

Claim:
A pharmaceutical composition comprising a compound having the structure of Formula (A): a tautomer thereof; or a pharmaceutically acceptable derivative thereof; wherein C=C is cis or trans; A represents an optionally substituted aromatic or non-aromatic 5-6 membered monocyclic ring, optionally containing 1-4 heteroatoms selected from N, O or S; or an optionally substituted aromatic or non-aromatic 8-12 membered bicyclic ring, optionally containing 1-6 heteroatoms selected from N, O or S; q is one or two; and each R is independently selected from the group consisting of hydrogen, halogen, hydroxyl, —NO 2 , —CN, an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic moiety; —OR R , —S(═O) n R d , —NR b R c , and —C(═O)R a ; wherein n is 0-2, R R is an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic moiety; R a , for each occurrence, is independently selected from the group consisting of hydrogen, hydroxy, optionally substituted aliphatic, heteroaliphatic, aryl and heteroaryl; R b and R c , for each occurrence, are independently selected from the group consisting of hydrogen; hydroxy; SO 2 R d ; optionally substituted aliphatic, heteroaliphatic, aryl and heteroaryl; R d , for each occurrence, is independently selected from the group consisting of hydrogen; —N(R e ) 2 ; optionally substituted aliphatic, aryl and heteroaryl; and R e , for each occurrence, is independently hydrogen or optionally substituted aliphatic; in an aqueous buffered saline containing about 40% to about 60% (v/v) polyethylene glycol 300 and about 5% to about 15% polysorbate 80; wherein the compound of Formula A has HGF/SF activity.